Clin2
NCT07741136Possibly a fitNot yet recruiting

Zoledronic acid for osteoporosis in dialysis patients

Chronic Kidney DiseaseOsteoporosisDialysis

Part of Bones, joints & muscles, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.

This study checks how the body handles a medicine called zoledronic acid in people with kidney disease who are on dialysis and have weak bones (osteoporosis). It may help doctors find the right dose to safely treat bone loss in this group.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
24 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have kidney disease and are on dialysis.
  • You have been told you have osteoporosis (weak bones).
  • You have not used a bisphosphonate medicine before (like zoledronic acid).
  • You do not have a planned dental surgery or tooth extraction in the next 12 months.
  • Your blood tests show your kidney function and other markers are within the study's needed range.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04608630Recruiting· Phase 2
Preventing bone loss in ICU patients with anti-bone drugs

This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.

Sydney, New South Wales
NCT06118905Recruiting· Phase 4
Osteoporosis medication to preserve muscle in seniors

This study tests whether an osteoporosis medication can help preserve muscle strength in older adults who live in senior facilities. It's for people age 65+ with fragile bones or low bone density who are at risk for falls and fractures.

Pittsburgh, Pennsylvania
NCT07406685Recruiting· Phase 4
Comparing two bone medicines after stopping denosumab

This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.

Taipei
NCT07281586Recruiting· Phase 4
Switching from Prolia to a different osteoporosis drug

This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.

Douliu, Taiwan
NCT05904353Recruiting
Care coordination program after hip fracture and osteoporosis

This trial aims to improve how primary care and hospital care work together to treat osteoporosis after a hip fracture. It may help by making follow-up treatment plans and communication clearer after your hip injury.

Lørenskog, Akershus
NCT06059222Recruiting· Phase 4
Optimizing Romosozumab for postmenopausal osteoporosis

This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.

Aarhus

Hear when a new Chronic kidney disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.